Corteva, Inc. $CTVA Stake Reduced by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company trimmed its holdings in Corteva, Inc. (NYSE:CTVA) by 7.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 360,696 shares of the company’s stock after selling 27,060 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Corteva were worth $30,193,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Corteva by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 80,536,951 shares of the company’s stock worth $5,398,392,000 after purchasing an additional 317,538 shares in the last quarter. State Street Corp boosted its holdings in Corteva by 3.7% during the fourth quarter. State Street Corp now owns 36,570,876 shares of the company’s stock worth $2,451,346,000 after buying an additional 1,290,071 shares in the last quarter. Franklin Resources Inc. grew its position in Corteva by 4.3% in the fourth quarter. Franklin Resources Inc. now owns 19,537,500 shares of the company’s stock worth $1,309,599,000 after buying an additional 805,873 shares during the last quarter. Harris Associates L P grew its position in Corteva by 168.1% in the fourth quarter. Harris Associates L P now owns 17,026,221 shares of the company’s stock worth $1,141,268,000 after buying an additional 10,675,052 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Corteva by 5.0% in the fourth quarter. Northern Trust Corp now owns 11,731,834 shares of the company’s stock valued at $786,385,000 after buying an additional 562,550 shares in the last quarter. Institutional investors own 81.54% of the company’s stock.

Corteva Price Performance

Shares of NYSE:CTVA opened at $78.98 on Friday. The company’s fifty day moving average is $82.15 and its two-hundred day moving average is $79.55. The company has a quick ratio of 1.03, a current ratio of 1.47 and a debt-to-equity ratio of 0.07. Corteva, Inc. has a 12-month low of $60.53 and a 12-month high of $90.97. The company has a market cap of $52.83 billion, a P/E ratio of 52.31, a price-to-earnings-growth ratio of 2.70 and a beta of 0.56.

Corteva (NYSE:CTVA) last released its earnings results on Thursday, July 30th. The company reported $2.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.24 by $0.06. Corteva had a return on equity of 10.24% and a net margin of 5.66%.The company had revenue of $6.38 billion during the quarter, compared to analyst estimates of $6.60 billion. During the same quarter in the prior year, the company earned $2.20 earnings per share. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. Equities analysts expect that Corteva, Inc. will post 3.76 earnings per share for the current fiscal year.

Corteva Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Tuesday, September 1st will be issued a $0.18 dividend. This represents a $0.72 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 1st. Corteva’s payout ratio is 42.35%.

Trending Headlines about Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Corteva reported second-quarter adjusted EPS of $2.30, exceeding the $2.24 analyst consensus and rising from $2.20 a year earlier. Seed pricing, productivity improvements, demand for newer genetics and traits, and growth in Crop Protection products supported margins. Reuters earnings report
• Positive Sentiment: The company raised its fiscal 2026 EPS outlook to $3.60-$3.80, reflecting strong first-half performance, operating improvements and growth platforms. Management also said it remains on track for the planned October 1 Vylor spin-off, a potential catalyst for improved business focus and valuation. Corteva first-half results and outlook
• Positive Sentiment: Analyst commentary remains broadly constructive: Corteva has outperformed the broader market and agriculture-focused ETFs, while brokerages maintain a consensus “Moderate Buy” rating. Momentum-focused analysis also highlights the company’s improving execution and fundamentals. Brokerage consensus rating
• Neutral Sentiment: Despite the earnings beat and higher guidance, one analysis argues that much of Corteva’s improved execution is already reflected in the stock, leaving limited upside unless earnings growth accelerates. Corteva valuation analysis
• Negative Sentiment: Second-quarter revenue was $6.38 billion, below the $6.60 billion consensus and down 1.2% year over year. The sales miss, together with competitive pricing pressure, appears to be the main reason the stock moved lower despite the profit beat and raised outlook. Corteva second-quarter earnings summary

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on CTVA shares. Deutsche Bank Aktiengesellschaft increased their price objective on Corteva from $90.00 to $100.00 in a research report on Monday, May 11th. Oppenheimer upped their target price on Corteva from $89.00 to $95.00 and gave the company an “outperform” rating in a report on Thursday, July 23rd. Bank of America increased their price target on Corteva from $90.00 to $96.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Weiss Ratings raised Corteva from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, May 7th. Finally, Mizuho boosted their price objective on Corteva from $96.00 to $97.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, Corteva presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.19.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid?2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.